Addendum re NVS-Alcon machinations: Inasmuch as NVS will be requited to shell out something in the neighborhood of $20B to satisfy Nestlé’s put option, the Alcon transaction is germane to investors in any biotech company in which NVS might have a buyout interest, including such companies as MNTA and IDIX.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”